At the core of STORM's R&D strategy is a close relationship with the company's scientific founders at the University of Cambridge. STORM works hand in hand with their research groups using cutting-edge techniques such as chemical biology, RNA-Seq and RNA mass spectrometry to elucidate the functional role of diverse RNA modifications and identify their protein writers, readers and erasers. The company uses the latest insights and emerging data from their collaboration to build a unique target discovery platform for the identification of new drug targets. Drawing on its emerging platform, it has established a pipeline of drug discovery programmes to develop novel, first-in-class drugs for the treatment of specific cancers with high unmet medical need.
Cambridge web design and marketing agency Postscript was commissioned to design and develop the company's new website and set about implementing a clean, modern, responsive design. The new site, built with the integration of the powerful but highly user-friendly open source content management framework ProcessWire, showcases STORM's cutting-edge scientific research and collects information about the company's board members, scientific founders and investors, which include Cambridge Innovation Capital plc (CIC) and Touchstone Innovations, formerly known as Imperial Innovations.
_____________________________